Here's a statement of the obvious: The opinions expressed here are those of the participants, not those of the Mutual Fund Observer. We cannot vouch for the accuracy or appropriateness of any of it, though we do encourage civility and good humor.
FYI: Against that backdrop, the Credit Suisse analysts insist that biotech is moving toward what they call a “Nirvana Model” of “unprecedented growth and profitability.”
